Ajanta Pharma Ltd News

Stocks with price-volume breakout: Ajanta Pharma, JBMA, Manappuram Finance

Ajanta Pharma, JBMA Auto and Manappuram Finance have seen strong price action backed by heavy trading volume in Wednesday's trading session.

Ajanta Pharma hits over 5-month high after partnering with Biocon

Ajanta Pharma share price rose as it has entered into an in-licensing agreement with Biocon Limited for the right to market Semaglutide

Ajanta Pharma signs pact with Biocon to sell semaglutide in 26 countries

Ajanta Pharma has signed an in-licensing pact with Biocon to market semaglutide across 26 countries in Africa, the Middle East and Central Asia, subject to approvals

Ajanta Pharma sets aside ₹1K crore for acquisitions to plug therapy gaps

Pain management, dermatology, nephrology and gynaecology are emerging as key focus areas

Neuland, Lupin, Divi's lead domestic, CDMO surge amid US generics headwinds

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

Ajanta Pharma offers growth potential amid US generic challenges: Nuvama

With larger generic companies facing growth challenges in the US in FY27E, Ajanta Pharma, analysts believe, offers a strong investment opportunity, driven by its branded market growth

Ajanta Pharma shares gain 3% on Q2FY26 results, dividend update; details

The dividend, the company said, will be paid on or after November 20, 2025

Tariff relief buzz lifts Nifty Pharma Index; Lupin, Aurobindo lead gains

Pharma stocks were rising in trade today as export concerns eased on US tariff report. Check out the top stocks that may benefit from US tariff relief

Ajanta Pharma newly rated 'Buy' at PL Capital; 26% upside seen; check TP

The brokerage analysis suggested that branded generics contributed to 74 per cent of Ajanta Pharma's revenue in FY25 and its branded generics business operates with a healthy OPM of 30 per cent